ISSN: 2167-7700
+44 1223 790975
Corrado Terranova
Italy
Research Article
Liposome Encapsulated Doxorubicin Citrate (Ledc) as an Alternative
Therapeutic Option for Patients with Recurrent Ovarian Cancer Suffering
from Doxorubicin-Related Cutaneous Toxicity
Author(s): Roberto Angioli, Michela Angelucci, Francesco Plotti, Corrado Terranova, Roberto Montera, Patrizio Damiani, Ester Valentina Cafa, Pierluigi Benedetti Panici and Angiolo GadducciRoberto Angioli, Michela Angelucci, Francesco Plotti, Corrado Terranova, Roberto Montera, Patrizio Damiani, Ester Valentina Cafa, Pierluigi Benedetti Panici and Angiolo Gadducci
Introduction: Pegylated liposomal doxorubicin (PLD) is considered to be the single-agent of first choice for patients with recurrent ovarian cancer following paclitaxel/carboplatin-based chemotherapy. However, this drug is associated with a local inflammatory tissue reaction, called palmoplantar erythrodysesthesia (PPE). A new liposomal formulation, known as Liposome Encapsulated Doxorubicin Citrate (LEDC), has been developed in the past decades to limit PPE. In this study we report our experience with LEDC in patients with recurrent ovarian cancer who discontinued doxil due to severe PPE.
Methods: The present retrospective study included 43 patients with recurrent ovarian cancer who were treated with LEDC administered at the dose of 50 mg/mq every 3 weeks until disease progression or unacceptable toxicity. Toxicity was graded according to the National Cancer Institute Common T.. View More»
DOI:
10.4172/2167-7700.1000113